newsfilter
← Latest News
Business Wire·

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

-- European Commission decision expected in the coming months -- If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc.